RECURSION PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M | $4.0M | $2.3M |
| Collaboration Revenue - Roche Genentech | — | — | $34.5M | $21.5M | $0 | $0 | — |
| Collaboration Revenue - Bayer | — | — | $10.1M | $18.3M | $10.2M | $2.4M | — |
| Grant Revenue | — | — | $0 | $0 | $0 | $1.6M | — |
| Cost of Revenue | $71.0M | $45.2M | $42.6M | $48.3M | $0 | $0 | — |
| Gross Profit | $3.7M | $13.6M | $2.0M | $-8.4M | $10.2M | $4.0M | — |
| Gross Margin | 5.0% | 23.1% | 4.4% | -21.2% | 100.0% | 100.0% | — |
| Operating Expenses | |||||||
| Research & Development | $475.3M | $314.4M | $241.2M | $155.7M | $135.3M | $63.3M | $45.8M |
| SG&A Expense | $176.6M | $178.2M | $110.8M | $81.6M | $57.7M | $25.3M | $19.0M |
| Operating Income | $-648.1M | $-479.0M | $-350.1M | $-245.7M | $-182.8M | $-84.6M | $-62.4M |
| Operating Margin | -867.9% | -814.1% | -785.6% | -616.8% | -1,793.3% | -2,127.6% | -2,692.6% |
| Interest Expense | — | — | $97.0K | $55.0K | $3.0M | $1.4M | $635.0K |
| Pretax Income | $-644.9M | $-464.8M | $-332.1M | $-239.5M | $-186.5M | — | — |
| Income Tax Expense | $-136.0K | $-1.1M | $-4.1M | $0 | $0 | $0 | $0 |
| Net Income | $-644.8M | $-463.7M | $-328.1M | $-239.5M | $-186.5M | $-87.0M | $-61.9M |
| Net Margin | -863.4% | -788.0% | -736.3% | -601.1% | -1,829.7% | -2,187.7% | -2,668.3% |
| EPS (Basic) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-0.67 | $-0.48 |
| EPS (Diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-0.67 | $-0.48 |
| Shares Outstanding (Basic) | 447.4M | 274.2M | 207.9M | 175.5M | 125.3M | 130.7M | 129.4M |
| Shares Outstanding (Diluted) | 447.4M | 274.2M | 207.9M | 175.5M | 125.3M | 130.7M | 129.4M |
| Dividends Per Share | — | — | — | — | — | — | — |